Trials · Topics · Thrombosis & Anticoagulation
Thrombosis & Anticoagulation clinical trials
33 Thrombosis & Anticoagulation trials (Classical Hematology) summarized for fellows and board review, newest first within each disease. Each summary covers design, results, toxicity and what changed in practice.
Jump to: VTE · Anticoagulation · VKA reversal
VTE (22)
- COBRRA NEJM 2026Apixaban was associated with significantly lower clinically relevant bleeding compared to rivaroxaban in acute VTE treatment over 3 months, without compromising...
- EPCAT III N Engl J Med 2026Aspirin alone was noninferior to a rivaroxaban-then-aspirin strategy for preventing symptomatic VTE after total hip or knee arthroplasty, with no clinically relevant...
- Hydra JAMA 2026In patients with active cancer and suspected PE, a D-dimer-based YEARS algorithm was noninferior to - and directionally safer than - proceeding directly to CTPA...
- Abelacimab VTE ppx NEJM 2021Factor XI inhibition with abelacimab showed noninferiority at 30 mg and superiority at 75 mg and 150 mg vs enoxaparin for VTE prevention after total knee...
- ADAM-VTE J Thromb Haemost 2020In this US trial, apixaban was associated with no major bleeds, borderline reduction in combined bleeding, and significantly lower VTE recurrence compared to...
- CARAVAGGIO NEJM 2020Apixaban was non-inferior to dalteparin for VTE recurrence in cancer patients without a significant increase in major bleeding, including in GI cancer subgroups...
- Hokusai-VTE Cancer NEJM 2018Edoxaban was non-inferior to dalteparin for the composite endpoint in cancer VTE but caused significantly more major bleeding, particularly in patients with GI...
- MARINER NEJM 2018Rivaroxaban post-discharge prophylaxis did not significantly reduce the primary composite of symptomatic VTE or VTE-related death in high-risk medical patients, and...
- SELECT-D JCO 2018Rivaroxaban reduced VTE recurrence by ~57% vs dalteparin in cancer patients but was associated with substantially higher clinically relevant bleeding, particularly in...
- EINSTEIN-CHOICE NEJM 2017Both rivaroxaban doses (20 mg and 10 mg once daily) were significantly superior to aspirin in preventing recurrent VTE after initial anticoagulation, with comparable...
- APEX NEJM 2016Betrixaban extended prophylaxis reduced VTE in enriched high-risk medical patients without significantly increasing major bleeding, meeting the pre-specified...
- AMPLIFY (VTE) NEJM 2013Apixaban was non-inferior to enoxaparin/warfarin for acute VTE treatment and caused significantly less major and overall bleeding, with a highly favorable net...
- AMPLIFY-EXT NEJM 2013Extended anticoagulation with apixaban at both a treatment dose (5 mg BID) and a thromboprophylactic dose (2.5 mg BID) reduced recurrent VTE by ~80% versus placebo...
- Hokusai-VTE NEJM 2013Edoxaban following initial parenteral anticoagulation was non-inferior to warfarin for acute VTE treatment with significant reduction in combined major/CRNMB...
- MAGELLAN NEJM 2013While rivaroxaban extended prophylaxis reduced VTE at 35 days, it significantly increased major and clinically relevant bleeding, resulting in an unfavorable...
- EINSTEIN-PE NEJM 2012Rivaroxaban was non-inferior to enoxaparin/VKA for acute PE treatment and caused significantly less major bleeding, supporting a simplified single-drug oral approach...
- WARFASA NEJM 2012Aspirin 100 mg/day significantly reduced recurrence of unprovoked VTE by ~42% compared to placebo after cessation of anticoagulation, with no excess major bleeding...
- EINSTEIN-DVT NEJM 2010Rivaroxaban as a single-drug oral regimen was non-inferior to enoxaparin/VKA for acute DVT treatment with a favorable bleeding profile, establishing DOACs as a...
- RE-COVER NEJM 2009Dabigatran was non-inferior to warfarin for VTE treatment with significantly lower overall and clinically relevant non-major bleeding, establishing dabigatran as an...
- CLOT NEJM 2003Dalteparin monotherapy was superior to VKA for preventing recurrent VTE in cancer patients (9% vs 17%), without significantly increasing major bleeding, establishing...
- ELATE NEJM 2003Conventional-intensity warfarin (INR 2.0-3.0) is significantly more effective than low-intensity warfarin (INR 1.5-1.9) for secondary VTE prevention, with no...
- PREVENT NEJM 2003Long-term low-intensity warfarin (INR 1.5-2.0) reduces recurrent VTE by 64% versus placebo after completing initial anticoagulation, with a modest and non-significant...
Anticoagulation (10)
- OCEANIC-STROKE NEJM 2026Asundexian added to antiplatelet therapy significantly reduced recurrent ischemic stroke after noncardioembolic stroke or TIA without increasing major bleeding...
- ANNEXA-4 NEJM 2019Andexanet alfa achieved excellent/good hemostasis in 82% of patients with major bleeding on factor Xa inhibitors, with rapid near-complete reduction in anti-Xa...
- Rivaroxaban vs warfarin in APS trial Annals of IM 2019Rivaroxaban did not demonstrate noninferiority to warfarin in thrombotic APS and was associated with more arterial thrombosis, particularly stroke. Warfarin remains...
- TRAPS trail Rivaroxaban vs warfarin in high-risk APLS Blood 2018In high-risk triple-positive antiphospholipid syndrome, rivaroxaban was associated with increased arterial thrombosis and bleeding vs warfarin. DOACs should be...
- REVERSE-AD NEJM 2017Idarucizumab achieved immediate, complete reversal of dabigatran anticoagulation in 100% of patients within minutes, with rapid hemostasis in bleeding patients and...
- ENGAGE-AF NEJM 2013Edoxaban 60 mg once daily was non-inferior to warfarin for stroke prevention in AF with significantly lower major bleeding and ICH, establishing it as an effective...
- ARISTOTLE NEJM 2011Apixaban was superior to warfarin for stroke/embolism prevention, major bleeding reduction, ICH reduction, and all-cause mortality in non-valvular AF, establishing it...
- AVERROES NEJM 2011Apixaban reduced stroke risk by 55% compared to aspirin in AF patients not on warfarin, without significant increase in major bleeding, definitively establishing that...
- ROCKET AF trial, rivaroxaban vs warfarin in Afib NEJM 2011Rivaroxaban was noninferior to warfarin for prevention of stroke or systemic embolism in nonvalvular atrial fibrillation, with similar bleeding.
- RE-LY NEJM 2009Dabigatran 150 mg BID was superior to warfarin for stroke prevention in AF with similar major bleeding, and significantly lower ICH risk, establishing the first DOAC...
VKA reversal (1)
- Sarode 2013 (4F-PCC) Circulation 20134F-PCC achieves noninferior 24-hour clinical hemostasis and markedly superior INR correction (62% vs 10% achieving INR ≤1.3 at 30 min) compared to plasma for urgent...